Cite
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series
MLA
Khaled A. Tolba, et al. “Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.” The Oncologist, vol. 26, no. 1, May 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c02aa2720d77d7d884d7950cdaec4012&authtype=sso&custid=ns315887.
APA
Khaled A. Tolba, Martin R. Jones, Christoph Heining, Valerie Gounant, Flavio Solca, Benjamin A. Weinberg, Daniel J. Renouf, Agnieszka Cseh, Domenico Trombetta, Alexander Drilon, Lucia Anna Muscarella, Stephen V. Liu, Yasushi Goto, Janessa Laskin, Michael Duruisseaux, Parneet Cheema, Eva Brandén, Jacques Cadranel, & Richard F. Schlenk. (2020). Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. The Oncologist, 26(1).
Chicago
Khaled A. Tolba, Martin R. Jones, Christoph Heining, Valerie Gounant, Flavio Solca, Benjamin A. Weinberg, Daniel J. Renouf, et al. 2020. “Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.” The Oncologist 26 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c02aa2720d77d7d884d7950cdaec4012&authtype=sso&custid=ns315887.